Navigation Links
EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases
Date:10/17/2007

WATERTOWN, Mass., Oct. 17 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimer's, Schizophrenia and Huntington's diseases.

EnVivo Pharmaceuticals is developing EVP6124, a selective, orally active Alpha 7 Nicotinic Acetylcholine Receptor Agonist for the treatment of cognitive deficits associated with Alzheimer's disease and Schizophrenia. The Company today announced the commencement of a second Phase I multiple ascending dose study in healthy young volunteers at very low doses to further establish safety factors and evidence of cognitive enhancement. In previously completed Phase I studies a positive signal consistent with the mechanism of action and suggestive of a pro-cognitive effect was shown.

In a related matter, the Company announced approval of an Investigational New Drug (IND) Application from the U.S. Food and Drug Administration for a Phase IIA Schizophrenia study that is scheduled to begin in early 2008. It is anticipated that Alpha 7 agonist compounds will improve cognitive function in Schizophrenia and Alzheimer's patients.

Additionally, the Company reported that a lead compound has emerged from its Histone Deacetylase Inhibitor (HDACi) program. The goal of the program is to further evaluate this lead compound with a view to potentially commencing clinical trials in 2008, in mutual agreement with partner MethylGene. The company believes that this lead compound represents one of the first highly potent, orally bio-available and brain-permeable HDAC inhibitors for neuro- degenerative diseases. HDAC inhibitors hold promise for treating the cognitive deficits of several diseases including Alzheimer's disease and Parkinson's Disease as well as slowing the progression of neuro-degenerative diseases such as Huntington's disease.

Finally, the Company announced the appointment of Maria S. Gawryl, 53, as Senior Director and program executive for the Alpha 7 initiative. Dr. Gawryl has more than 20 years of pharmaceutical experience with companies such as RenaMed Biologics, Biopure Corporation, Baxter and Bioscience associates, as well as research experience at academic institutions such as Harvard and Yale University School of Medicine. She has executed and completed numerous multinational clinical trials and over 250 preclinical studies. She holds a Bachelor of Science in Chemistry and Mathematics from Antioch College, a Ph.D. in Immunology/Biomedical Sciences from the University of Connecticut and completed post-doctoral research at Rush Medical College in Chicago.

"Our Company is continuing to make steady progress across all programs of our pipeline, so we are privileged to have such an experienced clinical pharmacologist join our teams to further advance these important programs into later-stage clinical trials" stated Kees Been, EnVivo's President and Chief Executive Officer.

EnVivo Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders including, Alzheimer's disease, Parkinson's disease and Huntington's disease. The company's lead programs include a Nicotinic Acetylcholine Receptor Agonist Program (alpha-7) for Alzheimer's disease and Schizophrenia, a Histone Deacetylase Inhibitor (HDACi) Program for Huntington's disease and several other programs such as the EVP2442 program for neuro-protection and the PDE10 inhibitor and gamma-secretase modulator programs. More information about EnVivo is available at http://www.envivopharma.com .


'/>"/>
SOURCE EnVivo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ANGELES , Dec. 8, 2016  Hanson ... manufacturing of dissolution testing and diffusion testing instruments ... been acquired by Teledyne Instruments, Inc. ("Teledyne"). The ... long-proven line of precision testing instruments, as well ... accelerating development of new products and services. ...
(Date:12/8/2016)... CANTEL MEDICAL CORP. (NYSE: CMD ) ... per diluted share, on a 22.1% increase in sales to ... 2016. This compares with net income of $14,254,000, or $0.34 ... quarter ended October 31, 2015. Non-GAAP net ... 2016 to $21,323,000, or $0.51 per diluted share, compared with ...
(Date:12/8/2016)... and SAN DIEGO , Dec. 8, 2016 ... solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech ... and the Genome Institute of Singapore ... new joint venture between Novogene and AITbiotech – will establish ... Singapore .   The new centre ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dianne Michael Insurance Agency, an ... County, is embarking on a charity drive with the aim of generating support ... orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers also ...
Breaking Medicine News(10 mins):